| Summary: | 碩士 === 國立臺灣大學 === 分子醫學研究所 === 102 === The purpose of the thesis was to investigate the methylation of various genes between patients with ovarian clear cell adenocarcinoma (OCCA) and ovarian endometrioid adenocarcinoma (OEA). In addition, we evaluated if methylation could be biomarkers in the chemo-response and outcome of the patients. The methylation statuses of eight candidate genes (RASSF1A, E-cadherin, DLEC1, RUNX3, SFRP1, SFRP5, PAX and LMX1A) were evaluated by methylation-specific polymerase chain reactions and capillary electrophoreses in 66 OCCA and 51 OEA patients. The clinico-pathologic parameters and outcomes of these patients were collected and analyzed. The frequencies of gene methylation in RASSF1A, E-cadherin, and DLEC1 were higher in the OCCA than in OEA. The chemo-resistant group had a significantly higher percentage of E-cadherin methylation than the chemo-sensitive group. Advanced stage and SFRP5 gene methylation were two death risk factors by multi-variate analyses in a total of 117 patients. In further analyses, gene methylation of E-cadherin, DLEC1, and SFRP5 were observed. Those with more than two out of the three gene methylations had shorter DFS and OS than those without any or with only one gene methylation. For 57 advance-staged women, paclitaxel chemotherapeutic group had longer OS than those without. As a result, we believe OCCA and OEA differed in gene methylation patterns. Methylation of E-cadherin, DLEC1, and SFRP5 genes appears to have the potential to become the specific biomarkers for OCCA and OEA patients.
|
|---|
